Overview

AXS-05 Phase II Trial on Smoking Behavior

Status:
Completed

Trial end date:
2019-03-31

Target enrollment:

Participant gender:

Summary

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

Phase:

Phase 2

Details

Lead Sponsor:

James Davis

Collaborator:

Axsome Therapeutics, Inc.

Treatments:

Bupropion
Dextromethorphan
Nicotine